ACEA 1021 data

COCN (Irvine, Calif.) announced Phase I safety data showing no evidence of side effects, including PCP-like adverse actions. The agent was well tolerated at doses above those expected to provide efficacy in stroke.

In the German trial with 40 healthy volunteers, 30 on drug and 10 on placebo, sedation, dizziness and nausea were seen at higher doses, but were not dose limiting. A Phase Ia trial is underway in the U.S. ...